Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentin Harter

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
World Journal of Urology|March 13, 2024
Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?Christian Pfister, Valentin Harter, Yves Allory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Reply to S. Zeng et alChristian Pfister, Valentin Harter, Yves Allory, et al.
Journal of Forensic Sciences|April 20, 2016
Age Estimation in Living Adults using 3D Volume Rendered CT Images of the Sternal Plastron and Lower ChestGuillaume Oldrini, Valentin Harter, Yannick Witte, et al.
European Urology Oncology|January 23, 2026
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key FactorChristian Pfister, Valentin Harter, Jacqueline Fontugne, et al.
Contemporary Clinical Trials Communications|February 22, 2020
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trialChristian Pfister, Valentin Harter, Yves Allory, et al.
Korean Journal of Anesthesiology|February 10, 2015
Biological evaluation of the effect of sugammadex on hemostasis and bleedingJulien Raft, Philippe Guerci, Valentin Harter, et al.
Brachytherapy|June 11, 2014
A case-control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapyAlain Haddad, Didier Peiffert, Michel Lapeyre, et al.
The Journal of Urology|December 28, 2023
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER TrialYves Allory, Stephane Culine, Clémentine Krucker, et al.
Oncology Reports|January 15, 2013
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteriaAlexandre Harlé, Maëva Lion, Nicolas Lozano, et al.
Virchows Archiv : an International Journal of Pathology|February 13, 2013
Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomasAlexandre Harlé, Benoit Busser, Marie Rouyer, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
World Journal of Urology|March 13, 2024
Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?Christian Pfister, Valentin Harter, Yves Allory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2022
Reply to S. Zeng et alChristian Pfister, Valentin Harter, Yves Allory, et al.
Journal of Forensic Sciences|April 20, 2016
Age Estimation in Living Adults using 3D Volume Rendered CT Images of the Sternal Plastron and Lower ChestGuillaume Oldrini, Valentin Harter, Yannick Witte, et al.
European Urology Oncology|January 23, 2026
Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key FactorChristian Pfister, Valentin Harter, Jacqueline Fontugne, et al.
Contemporary Clinical Trials Communications|February 22, 2020
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trialChristian Pfister, Valentin Harter, Yves Allory, et al.
Korean Journal of Anesthesiology|February 10, 2015
Biological evaluation of the effect of sugammadex on hemostasis and bleedingJulien Raft, Philippe Guerci, Valentin Harter, et al.
Brachytherapy|June 11, 2014
A case-control study of patients with squamous cell carcinoma of the oral cavity and oropharynx treated with pulsed-dose-rate brachytherapyAlain Haddad, Didier Peiffert, Michel Lapeyre, et al.
The Journal of Urology|December 28, 2023
Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER TrialYves Allory, Stephane Culine, Clémentine Krucker, et al.
Oncology Reports|January 15, 2013
Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteriaAlexandre Harlé, Maëva Lion, Nicolas Lozano, et al.
Virchows Archiv : an International Journal of Pathology|February 13, 2013
Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomasAlexandre Harlé, Benoit Busser, Marie Rouyer, et al.
Pageof 3